Cafepharma Today

June 3 2025 - Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Arrowhead commences dosing in Phase I/IIa obesity treatment trial
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Amid staff cuts, FDA looks to AI to 'optimize' reviews
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GSK Keen to Keep Some Emerging Markets Drugs
TheStreet.com
Friday, May 30, 2014 - 12:30pm
tags:
GSK, emerging markets
Keryx Biopharma: Approval Delay Does Not Change Zerenex Prospects Or Differentiation
Seeking Alpha
Friday, May 30, 2014 - 12:28pm
tags:
Keryx, Zerenex
[video]Supreme Court + Risky Drug Launch = Billions at Stake
Motley Fool
Friday, May 30, 2014 - 12:25pm
tags:
Supreme Court, Teva Pharmaceuticals, Copaxone, generics, MS, multiple sclerosis
Pfizer: Why A Major Acquisition Or Break-Up Is Needed
Seeking Alpha
Friday, May 30, 2014 - 12:23pm
tags:
Pfizer, M&A
Johnson & Johnson Collaborates with Aduro BioTech
Yahoo/Zacks.com
Friday, May 30, 2014 - 12:22pm
tags:
JNJ, Aduro BioTech, prostate cancer
AstraZeneca’s resistance efforts rely on cancer drug advances
FT.com
Friday, May 30, 2014 - 10:37am
tags:
AstraZeneca, MEDI4736
[video]Could This be Pfizer's Best Incoming Drug?
Motley Fool
Friday, May 30, 2014 - 10:15am
tags:
Pfizer, palbociclib, breast cancer
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Motley Fool
Friday, May 30, 2014 - 10:12am
tags:
Pfizer, AstraZeneca, Celgene, M&A
Italy to seek $1.6 billion damages from Roche, Novartis
Marketwatch
Thursday, May 29, 2014 - 1:14pm
tags:
Italy, Roche, Novartis, antitrust, Lucentis
Substance Over Style: How Niche Companies Alliqua And Horizon Are Being Overlooked
Seeking Alpha
Thursday, May 29, 2014 - 10:39am
tags:
Alliqua BioMedical, Horizon Pharma, wound care, arthritis
What Price Innovation? The Sovaldi Saga
Forbes
Thursday, May 29, 2014 - 9:43am
tags:
innovation, Sovaldi, Gilead Sciences, drug pricing, hepatitis C
Chelsea Therapeutics - Going Private Transaction Provides Significant Upside
Seeking Alpha
Thursday, May 29, 2014 - 9:35am
tags:
Chelsea Therapeutics, Lundbeck
Mylan launches generic version of GlaxoSmithKline's Malarone tablets
The Fly on the Wall
Thursday, May 29, 2014 - 9:28am
tags:
generics, Mylan, GSK, Malarone, malaria
Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS
Motley Fool
Thursday, May 29, 2014 - 9:17am
tags:
Vivus, Intercept Pharmaceuticals, M&A, Aspen Investments, OCA
Boston Therapeutics initiates Phase IIb study of Sugardown
The Fly on the Wall
Thursday, May 29, 2014 - 8:54am
tags:
Boston Therapeutics, Sugardown, diabetes
Immune Therapy’s Cancer Promise Creates Research Rush
Bloomberg
Thursday, May 29, 2014 - 8:52am
tags:
cancer immunotherapy, Merck, MK-3475, Roche, Yervoy, Bristol-Myers Squibb, Merck KGaA, AstraZeneca
Glaxo China sales staff seeks reimbursement for 'bribes,' FT says
The Fly on the Wall
Thursday, May 29, 2014 - 8:50am
tags:
GSK, bribery, China
Why Pfizer Will Never Be the Same Again
Motley Fool
Wednesday, May 28, 2014 - 7:51pm
tags:
Pfizer, AstraZeneca, restructuring
Medtronic settles U.S. kickbacks case over pacemakers
Yahoo/Reuters
Wednesday, May 28, 2014 - 4:43pm
tags:
pacemakers, Medtronic
Insurers scrutinize drug costs after $84,000 Sovaldi surprise
Yahoo/Reuters
Wednesday, May 28, 2014 - 2:01pm
tags:
drug pricing, insurance, Sovaldi, Gilead Sciences

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.